Tenax Therapeutics (TENX) Tops Q3 EPS by 6c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/21/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Supermicro probe finds no senior management link to export violations
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
Tenax Therapeutics Announces Third Quarter Fiscal Year 2015 Financial Results
March 18, 2015 6:00 AM EDT- Significant enrollment progress for Phase 3 LEVO-CTS trial in LCOS and LeoPARDS trial in septic shock
- Announced appointment of Paula Bokesch, M.D., as Chief Medical Officer
- Analyst Day on April 13 in New York City
- Conference call today at 8:30 am ET
MORRISVILLE, N.C.--(BUSINESS WIRE)-- Tenax Therapeutics, Inc. (NASDAQ: TENX), a specialty pharmaceutical company focused on developing and commercializing a portfolio of products for the critical care market, today announced financial results for the third quarter... More
